While co-targeting of ERBB receptors has been described to enhance the efficacy of BRAF inhibition in melanoma [46], our data suggest that MITFlow/AXLhigh melanomas with high RTK activity might preferentially benefit from such a combination treatment in contrast to MAPKi-resistant melanoma without or with only limited RTK activity, which provides a molecular rationale for patient stratification. This evidence concerns the gene BRAF and melanoma.